AP NEWS

Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - ResearchAndMarkets.com

July 13, 2018

DUBLIN--(BUSINESS WIRE)--Jul 13, 2018--The “Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report has been added to ResearchAndMarkets.com’s offering.

Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems. Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson’s.

The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease.

The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well.

Companies Mentioned:

3M New Ventures 4P Therapeutics 5AM Ventures Abbott ApoPharma Araclon Biotech ArmaGen Armistice Capital Arrien Pharmaceuticals Asceneuron AstraZeneca Atlas Venture Auckland City Hospital Avanir Pharmaceuticals Avant Diagnostics Axovant Sciences AZTherapies Azur Pharma Babraham Research Campus Bayer Ben Franklin Technology Partners BenevolentAI Bertin Bioreagent BIAL BioAdvance BioArctic BioElectron Technology Biogen BioReference Laboratories Biotie Therapeutics

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Pipeline Review: Marketed And Development Drugs

5. Parkinson’s Disease: UNMET Need Analysis

6. Drug Profiles: Phase III Molecules

7. Company Competitiveness Analysis

8. Mergers And Acquisitions

9. Kol Analysis

10. Funding And Investment Analysis

11. Survey Analysis

12. Appendix 1: Tabulated Data

13. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/research/pbs2hb/parkinsons?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180713005092/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/13/2018 04:59 AM/DISC: 07/13/2018 04:59 AM

http://www.businesswire.com/news/home/20180713005092/en

AP RADIO
Update hourly